Sensorium Therapeutics
PrivateLast Round
Series A
Extension
Aug 20, 2025
Total Funding Raised
$55M
Company Overview
Sensorium Therapeutics is a clinical-stage biotechnology company that develops nature-derived psychoactive medicines for mental and brain health conditions. The company was founded in 2021 by researchers from Massachusetts General Hospital and Harvard Medical School. Sensorium's proprietary Biodynamic Discovery Platform™ integrates artificial intelligence, chemistry, and neuroscience to identify and develop new drug candidates from plant and fungi-based compounds. Its lead program, SENS-01, is being developed for anxiety and depression. The U.S. FDA has cleared the Investigational New Drug (IND) application for its lead anxiety program, SNTX-2643, with first-in-human dosing expected to begin in Q3 2025.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Mental Health, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sensorium Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Sensorium Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Aug 20, 2025 | ||||
| Series A | Nov 8, 2022 |
Sensorium Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dolby Family Ventures | Series A Extension |
| H. Barton Asset Management | Series A Extension |
| Hatteras Venture Partners | Series A Extension |
| re.Mind Capital | Series A |
| Iter Investments | Series A |
| Mockingbird Capital Partners | Series A Extension |
| Palo Santo | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 9, 2025
Jacob Hooker, PhD, appointed as new Chief Executive Officer.
- Jul 9, 2025
Simba Gill appointed Executive Chairman of the Board of Directors.
Sensorium Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Sensorium Therapeutics's valuation, stock price, and market status.
